Borderline Resectable Pancreatic Cancer Clinical Trial
Official title:
Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04617821 -
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
|
Phase 3 | |
| Suspended |
NCT04090463 -
IORT on Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT04698915 -
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06384560 -
Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03850769 -
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03443921 -
Divestment for Artery-involved Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06345300 -
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
|
Phase 2 | |
| Active, not recruiting |
NCT02717091 -
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04855331 -
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
|
N/A |